Uncategorized
This week in Drug Discovery (11 – 15 May)
News round-up for 11 – 15 May by Bruno Quinney, Content Team at DDW.
This week, research has uncovered new treatment pathways for hard to treat breast cancers. Elsewhere, therapies given the green light could combat type 2 diabetes and generalised myasthenia gravis.
The top stories:
Research suggests new treatment pathway for triple-negative breast cancers
New research has uncovered how treatment-resistant cancer cells may drive poor outcomes for people with triple-negative breast cancer (TNBC).
Read more…
First GLP-1 gene therapy gets green light for diabetes trial
Fractyl Health has received Clinical Trial Application authorisation in the Netherlands to initiate the Phase I/II first-in-human study of RJVA-001, the first clinical candidate from the company’s Rejuva Smart GLP-1 gene therapy platform.
Read more…
FDA treatment approval brings ‘hope’ to gMG patients
The US Food and Drug Administration (FDA) has approved the first treatments for all serotypes of patients living with generalised myasthenia gravis (gMG).
Cystic fibrosis treatment could improve lung function
A new treatment for cystic fibrosis (CF) could improve lung function in patients, results suggest.
Read more…
AI not solving clinical trial flaws, report says
Analytics and data company Phesi revealed the findings from a global analysis of more than 600,000 clinical trial protocols.
The post This week in Drug Discovery (11 – 15 May) appeared first on Drug Discovery World (DDW).